$VRX Of the 25 tracked by Bloomberg, 18 still have buy ratings on Valeant shares. Another six rate the stock a hold, while only one, Dimitry Khmelnitsk at Veritas Investment Research, rates it a sell.
Lisa Hoppe 01:14 PM 10/22/2015
$VRX research #3 from Citron Research "Now Valeant has made new disclosures regarding its distribution channel, and they’ve led the company into a web of deception that … you have to read for yourselves." www.citronresearch.com/va...l-enron/
Lisa Hoppe 12:56 PM 10/03/2015
$VRX Citron Research published research #2 on Valeant "Investors, Politicians, and Concerned Citizens must note that Valeant raised the prices on the two key heart drugs in question the very next day after they acquired them … just to cover up for a bad quarter." www.citronresearch.com/ci...valeant/
David Lyons 12:01 PM 09/29/2015
$VRX heh... time to #sell the stocks don't recover at least for 6-12m after Citron research... or never recover!
Lisa Hoppe 11:36 AM 09/29/2015
$VRX BOOM... Citron Research published a research on Valeant. "As well as a major threat to the integrity of our entire healthcare system, Valeant (NYSE:VRX) is now the most devious three-cornered tax avoidance scheme we've ever seen." #sellwww.citronresearch.com/wh...granted/
John O'Donoghue 07:46 AM 08/21/2015
$VRX Valeant buys “female Viagra” maker Sprout but market is not aroused #bullish
Valeant Pharmaceuticals International Inc stock price chart
Valeant Pharmaceuticals International Inc financials
About Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.